Affiliation:
1. State Key Laboratory of Bioactive Molecules and Drug Gability Assessment, Jinan University, Guangzhou 510632, China
2. Institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, China
3. Biopharmaceutical R&D Center, Jinan University, Guangzhou 510632, China
Abstract
Atopic dermatitis (AD), a prevalent chronic inflammatory skin disorder, is marked by impaired skin barrier function and persistent pruritus. It significantly deteriorates patients’ quality of life, making it one of the most burdensome non-lethal skin disorders. Filaggrin plays a crucial role in the pathophysiology of barrier disruption in AD, interacting with inflammatory mediators. It is an integral part of the extracellular matrix architecture, serving to protect the skin barrier and attenuate the inflammatory cascade. In this study, we engineered a novel recombinant human filaggrin (rhFLA-10) expression vector, which was subsequently synthesized and purified. In vitro and ex vivo efficacy experiments were conducted for AD. rhFLA-10, at low concentrations (5 to 20 μg/mL), was non-toxic to HACaT cells, significantly inhibited the degranulation of P815 mast cells, and was readily absorbed by cells, thereby exerting a soothing therapeutic effect. Furthermore, rhFLA-10 demonstrated anti-inflammatory properties (p < 0.05). In vivo, efficacy experiments further substantiated that rhFLA-10 could effectively ameliorate AD in mice and facilitate the repair of damaged skin (p < 0.001). These findings underscore the considerable potential of rhFLA-10 in the treatment of AD.
Funder
National Key Research and Development program of China
Natural Science Foundation of Guangdong Province, China
Guangzhou Research and Development Plan in Key Fields, China
National Innovation and Entrepreneurship Training Program For Undergraduate
Reference43 articles.
1. Atopic dermatitis;Weidinger;Nat. Rev. Dis. Primers,2018
2. The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions;Hay;J. Investig. Dermatol.,2014
3. Filaggrin and beyond: New insights into the skin barrier in atopic dermatitis and allergic diseases, from genetics to therapeutic perspectives;Stefanovic;Ann. Allergy Asthma Immunol.,2023
4. Anti-atopic dermatitis effects of Parasenecio auriculatus via simultaneous inhibition of multiple inflammatory pathways;Kwon;BMB Rep.,2022
5. Zein, N.M. (2018). “Cpdx”, a Non-Steroidal Selective Glucocorticoid Receptor Agonistic Modulator (SEGRAM) Selectively Triggers the Beneficial Anti-Inflammatory Activity of Glucocorticoids, but Not Their Long-Term Debilitating Effects. [Ph.D. Thesis, Université de Strasbourg].